FDA outlines a laundry list of surrogate endpoints with an eye to expanding the roster for drug developers
The FDA on Wednesday published a list of surrogate endpoints to help inform drug developer discussions with relevant Center for Biologics Evaluation and Research …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.